Use of GLP-1s, especially semaglutide and liraglutide, may increase risk for nonarteritic anterior ischemic optic neuropathy ...

Adults with type 1 diabetes on multiple daily injection therapy saw no benefit in glycemic measures when adding on preprandial injections of short-acting exenatide, according to findings from a ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

A one-time gene modification may help the body produce its own 'natural Ozempic,' a study published this week on mice from ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Recent experiments on genetically altered mice have created buzz far beyond research circles. Instead of regular injections, ...

Scientists have gene-hacked mice to produce their own Ozempic-like enzymes, paving a path for humans to do so themselves one day. In a new study published in the journal Communications Medicine, ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

Ozzy Osbourne, Black Sabbath frontman, has died at the age of 76. He had suffered from numerous health problems and was ...

Nuvalent Inc. (NASDAQ:NUVL) is one of the best mid cap pharma stocks to buy. On July 21, Nuvalent announced that the first ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease.